Abstract
Healthy People 2010 aims at immunizing 60% of high-risk adults annually against influenza and once against pneumococcal disease. The aim of this study was to evaluate the use of a standardized approach to improve vaccination rates in patients with heart failure (HF); to determine whether disparities exist based on age, race, ethnicity, or sex at baseline and follow-up; and to evaluate the impact of clinical variables on the odds of being vaccinated. A prospective study of 549 indigent patients enrolled in a systolic HF disease management program (HFDMP) began enrollment from August 2007 to January 2009 at Jackson Memorial Hospital. Patients were interviewed at their initial visit for immunization status; those without vaccinations were offered the vaccines. Prevalence of vaccination (POV) for influenza and pneumococcal disease was obtained at baseline and at follow-up. The odds ratio for being vaccinated was calculated using logistic regression. The study population comprised mostly Hispanic (56%), black (37%), and male (70%) patients, with a mean age of 56±12 years and a mean ejection fraction of 25%±10%. The initial POV for both was 22% at baseline. At follow-up, POV improved to 60.5%. Of those not vaccinated at baseline, 17.5% refused vaccination. Odds ratios at baseline for age, race/ethnicity, and sex were 0.99 (P=99), 0.63 (P=08), and 0.62 (P=14), respectively. These did not change significantly at follow-up. Prevalence of vaccination in our cohort was low. Enrollment into the HFDMP improved immunization prevalence without creating age, race, ethnicity, or sex disparities. Congest Heart Fail.
| Original language | English |
|---|---|
| Pages (from-to) | 278-283 |
| Number of pages | 6 |
| Journal | Congestive Heart Failure |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 1 2010 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Emergency Medicine
- Emergency
Cite this
Prevalence of Vaccination Rates in Systolic Heart Failure : A Prospective Study of 549 Patients by Age, Race, Ethnicity, and Sex in a Heart Failure Disease Management Program. / Hebert, Kathy; Marzouka, George; Arcement, Lee; Julian, Elyse; Cortazar, Frank; Dias, Andre; Tamariz, Leonardo.
In: Congestive Heart Failure, Vol. 16, No. 6, 01.11.2010, p. 278-283.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevalence of Vaccination Rates in Systolic Heart Failure
T2 - A Prospective Study of 549 Patients by Age, Race, Ethnicity, and Sex in a Heart Failure Disease Management Program
AU - Hebert, Kathy
AU - Marzouka, George
AU - Arcement, Lee
AU - Julian, Elyse
AU - Cortazar, Frank
AU - Dias, Andre
AU - Tamariz, Leonardo
PY - 2010/11/1
Y1 - 2010/11/1
N2 - Healthy People 2010 aims at immunizing 60% of high-risk adults annually against influenza and once against pneumococcal disease. The aim of this study was to evaluate the use of a standardized approach to improve vaccination rates in patients with heart failure (HF); to determine whether disparities exist based on age, race, ethnicity, or sex at baseline and follow-up; and to evaluate the impact of clinical variables on the odds of being vaccinated. A prospective study of 549 indigent patients enrolled in a systolic HF disease management program (HFDMP) began enrollment from August 2007 to January 2009 at Jackson Memorial Hospital. Patients were interviewed at their initial visit for immunization status; those without vaccinations were offered the vaccines. Prevalence of vaccination (POV) for influenza and pneumococcal disease was obtained at baseline and at follow-up. The odds ratio for being vaccinated was calculated using logistic regression. The study population comprised mostly Hispanic (56%), black (37%), and male (70%) patients, with a mean age of 56±12 years and a mean ejection fraction of 25%±10%. The initial POV for both was 22% at baseline. At follow-up, POV improved to 60.5%. Of those not vaccinated at baseline, 17.5% refused vaccination. Odds ratios at baseline for age, race/ethnicity, and sex were 0.99 (P=99), 0.63 (P=08), and 0.62 (P=14), respectively. These did not change significantly at follow-up. Prevalence of vaccination in our cohort was low. Enrollment into the HFDMP improved immunization prevalence without creating age, race, ethnicity, or sex disparities. Congest Heart Fail.
AB - Healthy People 2010 aims at immunizing 60% of high-risk adults annually against influenza and once against pneumococcal disease. The aim of this study was to evaluate the use of a standardized approach to improve vaccination rates in patients with heart failure (HF); to determine whether disparities exist based on age, race, ethnicity, or sex at baseline and follow-up; and to evaluate the impact of clinical variables on the odds of being vaccinated. A prospective study of 549 indigent patients enrolled in a systolic HF disease management program (HFDMP) began enrollment from August 2007 to January 2009 at Jackson Memorial Hospital. Patients were interviewed at their initial visit for immunization status; those without vaccinations were offered the vaccines. Prevalence of vaccination (POV) for influenza and pneumococcal disease was obtained at baseline and at follow-up. The odds ratio for being vaccinated was calculated using logistic regression. The study population comprised mostly Hispanic (56%), black (37%), and male (70%) patients, with a mean age of 56±12 years and a mean ejection fraction of 25%±10%. The initial POV for both was 22% at baseline. At follow-up, POV improved to 60.5%. Of those not vaccinated at baseline, 17.5% refused vaccination. Odds ratios at baseline for age, race/ethnicity, and sex were 0.99 (P=99), 0.63 (P=08), and 0.62 (P=14), respectively. These did not change significantly at follow-up. Prevalence of vaccination in our cohort was low. Enrollment into the HFDMP improved immunization prevalence without creating age, race, ethnicity, or sex disparities. Congest Heart Fail.
UR - http://www.scopus.com/inward/record.url?scp=78649466235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649466235&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7133.2010.00190.x
DO - 10.1111/j.1751-7133.2010.00190.x
M3 - Article
C2 - 21091613
AN - SCOPUS:78649466235
VL - 16
SP - 278
EP - 283
JO - Congestive Heart Failure
JF - Congestive Heart Failure
SN - 1527-5299
IS - 6
ER -